Get an overview of ADVAIR HFA (fluticasone propionate and salmeterol xinafoate aerosol, metered), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in ADVAIR HFA can be sold under different names. Show Refer to the “Also Known As” section to reference different products that include the same medication as ADVAIR HFA. Brand Name: ADVAIR HFA
Generic Name: FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE Drug Type: HUMAN PRESCRIPTION DRUG Route: RESPIRATORY (INHALATION) Dosage Form: AEROSOL, METERED Data Current As Of: 2020-06-08
indications & usageADVAIR HFA is indicated for the twice-daily treatment of asthma in patients aged 12 years and older. ADVAIR HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA). Important Limitation of Use ADVAIR HFA is NOT indicated for the relief of acute bronchospasm. ADVAIR HFA is a combination product containing a corticosteroid and a long-acting beta2‑adrenergic agonist (LABA) indicated for the twice-daily treatment of asthma in patients aged 12 years and older. (1) Important limitation of use: Not indicated for relief of acute bronchospasm. (1) patient counseling informationAdvise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Serious Asthma-Related Events Inform patients with asthma that LABA when used alone increases the risk of asthma-related hospitalization or asthma-related death. Available data show that when ICS and LABA are used together, such as with ADVAIR HFA, there is not a significant increase in the risk of these events. Not for Acute Symptoms Inform patients that ADVAIR HFA is not meant to relieve acute asthma symptoms and extra doses should not be used for that purpose. Advise patients to treat acute asthma symptoms with an inhaled, short-acting beta2-agonist such as albuterol. Provide patients with such medication and instruct them in how it should be used. Instruct patients to seek medical attention immediately if they experience any of the following:
Tell patients they should not stop therapy with ADVAIR HFA without physician/provider guidance since symptoms may recur after discontinuation. Do Not Use Additional Long-acting Beta2-agonists Instruct patients not to use other LABA for asthma. Local Effects Inform patients that localized infections with Candida albicans occurred in the mouth and pharynx in some patients. If oropharyngeal candidiasis develops, treat it with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing therapy with ADVAIR HFA, but at times therapy with ADVAIR HFA may need to be temporarily interrupted under close medical supervision. Advise patients to rinse the mouth with water without swallowing after inhalation to help reduce the risk of thrush. Pneumonia Patients with COPD have a higher risk of pneumonia; instruct them to contact their healthcare providers if they develop symptoms of pneumonia. Immunosuppression Warn patients who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physicians without delay. Inform patients of potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Hypercorticism and Adrenal Suppression Advise patients that ADVAIR HFA may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, inform patients that deaths due to adrenal insufficiency have occurred during and after transfer from systemic corticosteroids. Patients should taper slowly from systemic corticosteroids if transferring to ADVAIR HFA. Immediate Hypersensitivity Reactions Advise patients that immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ADVAIR HFA. Patients should discontinue ADVAIR HFA if such reactions occur. Reduction in Bone Mineral Density Advise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk. Reduced Growth Velocity Inform patients that orally inhaled corticosteroids, including fluticasone propionate, may cause a reduction in growth velocity when administered to pediatric patients. Physicians should closely follow the growth of children and adolescents taking corticosteroids by any route. Glaucoma and Cataracts Advise patients that long-term use of ICS may increase the risk of some eye problems (cataracts or glaucoma); consider regular eye examinations. Risks Associated with Beta-agonist Therapy Inform patients of adverse effects associated with beta2‑agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. Trademarks are owned by or licensed to the GSK group of companies. GlaxoSmithKline Research Triangle Park, NC 27709 ©2019 GSK group of companies or its licensor. ADH:14PI
PRINCIPAL DISPLAY PANEL NDC 0173-0715-20 ADVAIR HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg* inhalation aerosol) 12 g For oral inhalation with ADVAIR HFA actuator only. *Contents: Each canister contains a microcrystalline suspension of fluticasone propionate and salmeterol xinafoate in propellant HFA-134a(1,1,1,2,-tetrafluoroethane). Each actuation delivers 45 mcg of fluticasone propionate and 30.45 mcg of salmeterol xinafoate equivalent to 21 mcg of salmeterol base from the mouthpiece. See prescribing information for dosage information. RX only With Counter 120 Metered Actuations ©2019 GSK group of companies or its licensor.
PRINCIPAL DISPLAY PANEL NDC 0173-0716-20 ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg* inhalation aerosol) 12 g For oral inhalation with ADVAIR HFA actuator only. *Contents: Each canister contains a microcrystalline suspension of fluticasone propionate and salmeterol xinafoate in propellant HFA-134a(1,1,1,2,-tetrafluoroethane). Each actuation delivers 115 mcg of fluticasone propionate and 30.45 mcg of salmeterol xinafoate equivalent to 21 mcg of salmeterol base from the mouthpiece. See prescribing information for dosage information. RX only With Counter 120 Metered Actuations ©2019 GSK group of companies or its licensor.
PRINCIPAL DISPLAY PANEL NDC 0173-0717-20 ADVAIR HFA 230/21 (fluticasone propionate 230 mcg and salmeterol 21 mcg* inhalation aerosol) 12 g For oral inhalation with ADVAIR HFA actuator only. *Contents: Each canister contains a microcrystalline suspension of fluticasone propionate and salmeterol xinafoate in propellant HFA-134a(1,1,1,2,-tetrafluoroethane). Each actuation delivers 230 mcg of fluticasone propionate and 30.45 mcg of salmeterol xinafoate equivalent to 21 mcg of salmeterol base from the mouthpiece. See prescribing information for dosage information. RX only With Counter 120 Metered Actuations ©2019 GSK group of companies or its licensor.
also known asWhy should you rinse your mouth after using Advair?Rinse your mouth with water without swallowing after each dose of ADVAIR HFA. This will help lessen the chance of getting a yeast infection (thrush) in your mouth and throat. Call your healthcare provider or get medical care right away if: your breathing problems get worse.
What happens if you don't Rinse your mouth after using Advair?When you breathe in your steroid inhaler medication, a small amount of steroid can stick to your mouth and throat as it makes its way into your lungs to help you breathe. If this small amount of steroid is not rinsed out from the inside of your mouth or throat, it can cause a fungal infection known as thrush.
What happens if you drink water after inhaler?If you are using a corticosteroid inhaler, gargle and rinse out your mouth with water after use. Do not swallow the water. Swallowing the water will increase the chance that the medicine will get into your bloodstream. This may make it more likely that you will have side effects.
When should you rinse your mouth after using an inhaler?Important tips: If you use a steroid inhaler, then you should rinse out your mouth with water and spit after use to prevent thrush and voice changes. You can do this with any inhaler.
|